Glenmark Q4FY26: EBITDA up 36%, margin at 20.2%

Results miss expectations despite a margin surprise

Glenmark Pharmaceuticals’ March-quarter results (Q4FY26) missed expectations, even as profitability improved sharply on operating cost control. The company reported EBITDA of ₹763 crore, up 36% year-on-year, helped by slower growth in raw material costs and other expenses. EBITDA margin expanded by 300 basis points to 20.2%, indicating better operating leverage in the quarter. Still, the market’s immediate reading of the results remained cautious. The stock fell about 4% over the past two trading sessions after the results. The near-term investor focus, as reflected in commentary around the earnings, is shifting towards core execution rather than one-off gains.

What supported EBITDA growth in Q4FY26

The primary driver flagged for the stronger EBITDA was slower growth in key cost lines, including raw materials and other expenses. Margin expansion of 300 basis points to 20.2% suggests the benefits were meaningful at the operating level. The quarter’s EBITDA growth came even as broader expectations were not met, which points to other elements of the print that did not land well with the Street. Management commentary also referenced operational challenges in an earlier quarter linked to a warehouse shift, implying some volatility in execution across quarters. Executives indicated that performance would be “better than what we have been expecting in quarter 3,” and pointed to new launches as a support for upcoming growth. In particular, the US business was cited as an area where growth could improve in the coming quarter as launches pick up.

Stock reaction: near-term dip, but recent rally also in view

The immediate post-result reaction was negative, with the stock down about 4% over the last two sessions. At the same time, the broader trading pattern described in the provided context shows the stock had risen 12% over the past 12 trading days since June 25. That surge was linked to the launch of the lung cancer treatment drug Tevimbra in India, following approval by the Central Drugs Standard Control Organisation. Together, these moves show a market that is responding quickly to both earnings delivery and product catalysts. Investors appear to be separating quarter-to-quarter earnings volatility from medium-term execution signals.

Investors shift attention to core execution beyond one-off gains

A key theme in the commentary is that investors are now looking “past one-off licensing gains” and tracking core operational execution to judge FY27 growth. Management has discussed a core business margin target for FY27 of close to 23%. There was also discussion around a margin improvement trajectory, including references to a 150 basis point improvement “from here on,” in the context of guidance and operational normalization. The focus on core metrics is significant for a company where business lines and geographies can have different margin profiles. It also puts execution in launches, supply chain stability, and mix improvement at the center of market expectations.

FY27 outlook: core business margin near 23%

In the earnings-related commentary, Glenmark guided to a core business margin close to 23% for FY27. This target is being positioned alongside a “good pipeline” across markets. The company also highlighted positive developments such as Monroe “getting cleared from FDA,” and noted that commercial production has started and should “start contributing slowly” to the P&L. In Europe, Glenmark said it launched Winlevi in the UK and expects it to be launched in a larger EU market. Management added that emerging markets continue to drive strong growth and that there is “good traction” across geographies.

India formulations: reported growth muted, but secondary sales stronger

For India formulations, Q4 sales were ₹943 crore (₹9,430 million), up about 0.4% year-on-year from ₹939.1 crore (₹9,391 million). The company said reported sales in India were impacted by three main factors: weak growth in the acute respiratory market due to low seasonal pickup, a highly competitive diabetes market that led to a 10% decline for Glenmark in the quarter, and the discontinuation of select non-core, low-margin brands in hospital and trade generics to improve overall business margins. Despite the lower reported growth, Glenmark stated it continued to outperform the Indian Pharmaceutical Market (IPM) on secondary sales. As per IQVIA, Glenmark’s India formulation business recorded growth of 10.3% in the fourth quarter, and 12% for MAT March 2025. This compared with overall market growth of 6% in Q4 and 7.7% for the MAT March period.

India growth target: 10% to 15% range, supported by launches

Management described India as a “very strong franchise” and said the business should continue to grow in the 10% to 15% range. Glenn Saldanha said Glenmark expects India growth at a 10% to 15% CAGR over the next two to three years. The company also highlighted recent brand actions and launches, including Tevimbra and Brukinsa, and said these cover a large patient base across multiple solid tumors and hematological malignancies. The stated strategy also includes continuing product introductions, with an expectation to sustain a run rate of 10 to 11 product launches every year. In another update, management flagged oncology launches such as tezilizumab and zanubrutinib, with expectations that both could launch in early July and be a near-term growth driver.

Other business lines: consumer care strength, North America remains tough

The context also notes that Glenmark reported 12.8% revenue growth for FY25, driven by European expansion and consumer care success, even as North America faced setbacks. Glenmark’s India Consumer Care business saw 23.5% year-on-year growth in Q4, supported by flagship brands such as Candid and La Shield. By contrast, the North America business recorded a 5.4% year-on-year revenue decline in Q4, attributed to a lack of meaningful launches. The company’s US business was described as “challenging,” with expected improvements only from FY26 onwards due to delayed product launches. These split trends matter because the pace of new launches and the regional mix can influence consolidated margins.

Guidance snapshot: FY26 growth and margin targets

Management and investor relations commentary included multiple guidance points for FY26. Utkarsh Gandhi, Senior General Manager, Investor Relations, said Glenmark is guiding for revenue growth of 10% to 12% and an EBITDA margin of 19% to 20%, along with expected cash generation of ₹300 crore to ₹400 crore. Separately, the company’s CFO indicated that post Q4, the company should see closer to the 19% margin that was guided, alongside 10% to 12% topline growth. Another management comment maintained overall guidance of 10% to 15% top line growth for the full year. The presence of multiple ranges highlights why investors are concentrating on delivery and visibility by geography and product pipeline.

Key numbers and reference points

Market impact and why the quarter matters

The quarter reinforced two market drivers for Glenmark’s stock: operating margin trajectory and the cadence of new launches. The margin expansion to 20.2% in Q4FY26 is a positive data point, but the miss versus expectations and the 4% two-session decline show that investors want cleaner earnings visibility. India remains important, with management reiterating a 10% to 15% growth ambition and pointing to oncology and other launches as incremental drivers. The difference between reported India formulation growth (0.4% YoY) and secondary-sales growth (10.3% in Q4, 12% MAT) is also central to how investors interpret demand versus invoicing and portfolio changes. In the US, the commentary stays cautious, with performance tied to the pace of launches and the resolution of delays. In Europe and emerging markets, launches like Winlevi and continued traction were positioned as supportive.

Conclusion

Glenmark’s Q4FY26 results delivered a sharp EBITDA increase to ₹763 crore and a 300 basis point margin expansion to 20.2%, but fell short of expectations and triggered a short-term stock decline. The next phase of investor attention is likely to remain on core execution, especially delivery against FY26 growth and margin guidance and the FY27 core margin target of about 23%. Management’s near-term focus includes new product launches, gradual contribution from FDA-cleared Monroe, and scaling brands across India and Europe. With multiple growth ranges discussed for FY26 and a clear margin ambition for FY27, upcoming quarters will be watched for consistency in launches and operating delivery.